Quantbot Technologies LP Has $8.63 Million Position in DexCom, Inc. (NASDAQ:DXCM)

Quantbot Technologies LP lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 698.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 128,682 shares of the medical device company’s stock after purchasing an additional 112,567 shares during the period. Quantbot Technologies LP’s holdings in DexCom were worth $8,627,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Jennison Associates LLC increased its position in DexCom by 1,683.2% during the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock worth $464,782,000 after buying an additional 6,544,102 shares during the last quarter. Legal & General Group Plc increased its holdings in shares of DexCom by 1.7% during the 2nd quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock worth $339,352,000 after acquiring an additional 49,076 shares during the last quarter. Westfield Capital Management Co. LP raised its stake in DexCom by 44.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock valued at $190,532,000 after acquiring an additional 876,739 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in DexCom by 11.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,734,155 shares of the medical device company’s stock valued at $183,298,000 after purchasing an additional 288,381 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its position in DexCom by 16.9% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock worth $276,538,000 after purchasing an additional 353,019 shares during the period. 97.75% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

DXCM has been the topic of several research analyst reports. Leerink Partners dropped their price objective on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Barclays reduced their price objective on DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a report on Monday, July 29th. Stifel Nicolaus increased their price objective on DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, August 23rd. Finally, Raymond James cut their price target on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research note on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and a consensus target price of $104.59.

Insider Activity at DexCom

In other news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. This trade represents a 0.56 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. This trade represents a 0.28 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,431 shares of company stock worth $399,319 in the last three months. 0.30% of the stock is owned by insiders.

DexCom Stock Up 6.9 %

Shares of DXCM opened at $77.83 on Tuesday. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The stock has a 50 day simple moving average of $70.76 and a two-hundred day simple moving average of $88.93. The firm has a market cap of $30.40 billion, a P/E ratio of 46.60, a P/E/G ratio of 2.23 and a beta of 1.17.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.